A A A

Institute News

Seminar on T-cell receptor-mediated decision making

Dr John James will be speaking on Exploring the mechanism of T-cell receptor-mediated decision making: how does a receptor count to ten? as part of the Institute's seminar series, on 24 April. More...

PI3K enzymes in immmune activation: forthcoming seminar, 10 April

Dr Klaus Okkenhaug has a long-standing interest in the roles of phosphoinositide 3-kinase (PI3K) enzyme isoforms in immune activation, particularly in T and B cells. His research group is based at the Laboratory of Lymphocyte Signalling and Development at the Babraham Institute and he currently holds a Wellcome Trust New Investigator Award. More...

Research

The Institute focusses on “bench to bedside” translational research to develop vaccinations, gene therapy and cell therapy to target immune-related conditions, as well as new types of transplant.  Clinical areas include:

  • cancer and leukaemia
  • chronic infections such as HIV, viral hepatitis and tuberculosis
  • auto-immune diseases including diabetes, scleroderma and inflammatory bowel disease
  • inherited immunodeficiency
  • other rare diseases such as haemophilia and amyloidosis
  • tissue and organ transplantation.
Prof Lucy Walker and HRH the Duke of York

Specific projects to improve early diagnosis and therapeutic options include:

  • Successful development of gene therapy for haemophilia B, and expanding this to other forms of haemophilia and to lysosomal storage diseases.
  • Improviding leukaemia immunotherapy through new lentiviral-vector vaccines targetting skin dendritic cells.
  • Developing new vaccination protocols to prevent viral disease in transplant patients
  • Adoptive cell therapy for leukaemia/lymphoma and viral infection
  • Innovative gene therapies for leukaemia, solid cancers and chronic infection
  • Discovering the genetic basis of certain forms of immunodeficiency and autoimmune conditions such as inflammatory bowel disease, facilitating early diagnosis and treatment
  • New biological therapies for patients with scleroderma, rheumatoid arthritis and pulmonary arterial hypertension
  • Tissue engineering and artificial organs for transplantation
  • Immune therapy for type 1 diabetes
  • Immune regulation and transplantation immunity
  • Hepatitis C virus cell-entry and antibody modulation.

Find out more about our researchers.

Page last modified on 29 jul 13 15:33